Ulus Salih Akarca1, Belkis Unsal2, Orhan Sezgin3, Kendal Yalcin4, Meral Akdogan5, Can Gonen6, Feyza Gunduz7, Seren Ozenirler8, Abdullah Sonsuz9, Dinc Dincer10, Salim Basol Tekin11, Idris Yucel12, Hakan Akbulut13, Canan Alkım14, Ozgur Ozyilkan15, Arzu Baygul16, Zeynep Merve Cevik17, Ramazan Idilman18, On Behalf Of K Registry Study Group19. 1. Department of Gastroenterology, Ege University Faculty of Medicine, Izmir, Turkey. 2. Clinic of Gastroenterology, Izmir Ataturk Training and Research Hospital, Izmir, Turkey. 3. Department of Gastroenterology, Mersin University Faculty of Medicine, Mersin, Turkey. 4. Department of Gastroenterology, Dicle University Faculty of Medicine, Diyarbakir, Turkey. 5. Clinic of Gastroenterology, Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey. 6. Clinic of Gastroenterology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. 7. Clinic of Gastroenterology, Marmara University Faculty of Medicine Pendik Training and Research Hospital, Istanbul, Turkey. 8. Department of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey. 9. Department of Gastroenterology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey. 10. Department of Gastroenterology, Akdeniz University Faculty of Medicine, Antalya, Turkey. 11. Department of Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey. 12. Department of Oncology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey. 13. Department of Oncology, Ankara University Faculty of Medicine, Ankara, Turkey. 14. Clinic of Gastroenterology, Sisli Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. 15. Department of Oncology, Adana Baskent University Faculty of Medicine, Adana, Turkey. 16. Department of Biostatistics, Koc University School of Medicine, Istanbul, Turkey. 17. Medical Management, Bayer Türk, Istanbul, Turkey. 18. Department of Gastroenterology, Ankara University Faculty of Medicine, Turkey. 19. on behalf of 3K Registry Study Group.
Abstract
AIMS: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey. METHODS: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study. Data on patient characteristics, etiologies of HCC, laboratory values, and tumor characteristics and stages were recorded at study enrollment. RESULTS: HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and NAFLD (3.5%), as the major etiologies. Considering that 51.6% of the patients had >5 cm HCC, 44% were Child-Pugh B/C and 57% were BCLC B-D, it appears that a significant group of HCC patients were diagnosed at advanced stages. Of 540 patients, 271 (50.2%) were referred or applied with the diagnosis of HCC. Patients with HCC at presentation had larger tumor size (median (min-max) 6.6 (0-30) vs. 4.8 (0-90) cm, P < .001) and more advanced BCLC stage (Stage C-D in 40.8% vs. 26.4%, respectively, P = .005), compared to patients who were diagnosed during follow-up. CONCLUSIONS: Our findings revealed that HBV infection was the leading etiology and a moderate-to-advanced disease was evident in more than half of patients at the time of diagnosis. HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.
AIMS: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey. METHODS: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study. Data on patient characteristics, etiologies of HCC, laboratory values, and tumor characteristics and stages were recorded at study enrollment. RESULTS: HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and NAFLD (3.5%), as the major etiologies. Considering that 51.6% of the patients had >5 cm HCC, 44% were Child-Pugh B/C and 57% were BCLC B-D, it appears that a significant group of HCC patients were diagnosed at advanced stages. Of 540 patients, 271 (50.2%) were referred or applied with the diagnosis of HCC. Patients with HCC at presentation had larger tumor size (median (min-max) 6.6 (0-30) vs. 4.8 (0-90) cm, P < .001) and more advanced BCLC stage (Stage C-D in 40.8% vs. 26.4%, respectively, P = .005), compared to patients who were diagnosed during follow-up. CONCLUSIONS: Our findings revealed that HBV infection was the leading etiology and a moderate-to-advanced disease was evident in more than half of patients at the time of diagnosis. HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.
Authors: Debra T Choi; Hye-Chung Kum; Sulki Park; Robert L Ohsfeldt; Yu Shen; Neehar D Parikh; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-10-26 Impact factor: 11.382